Jin Medical International Ltd. ZJYL

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS0.01

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Revenue $20.7M$23.5M$19.8M$19.2M$20.8M—
Cost of revenue $14.6M$14.0M$13.0M$13.0M$14.4M—
Gross profit $6.0M$9.5M$6.8M$6.2M$6.4M—
R&D $1.6M$1.5M$1.5M$1.9M$1.6M—
SG&A $2.5M$3.3M$1.9M$1.8M$1.7M—
Total operating expenses $5.4M$5.9M$3.9M$4.1M$3.7M—
Operating income $608.2K$3.6M$2.9M$2.1M$2.6M—
Interest expense ——$182.7K$181.6K$9.5K—
Pre-tax income $1.6M$4.2M$3.2M$2.7M$2.9M—
Income tax $214.6K$763.9K$343.7K$36.1K$248.6K—
Net income $1.2M$3.7M$2.9M$2.7M$2.6M—
EPS, basic 0.010.020.020.020.02—
EPS, diluted 0.010.020.020.020.02—
Shares, diluted (wtd. avg.) 156.5M156.5M145.1M135.0M135.0M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents $7.5M$8.1M$6.9M$4.8M$3.7M$1.7M
Short-term investments $22.2M$18.6M$9.8M$2.3M——
Receivables $5.8M$5.9M$3.3M$3.8M——
Inventory $4.9M$5.2M$5.1M$6.7M——
Total current assets $44.1M$42.8M$31.1M$18.9M——
Property, plant and equipment $7.9M$1.5M$1.5M$1.6M——
Other intangibles $1.1M$1.1M$154.4K———
Total assets $53.4M$45.8M$32.9M$20.9M——
Accounts payable $3.3M$3.0M$3.4M$4.1M——
Short-term debt $18.8M$11.3M$4.1M———
Total current liabilities $23.8M$17.2M$8.9M$5.7M——
Total liabilities $23.8M$17.2M$8.9M$5.7M——
Retained earnings $20.9M$20.0M$16.9M$14.4M——
Total equity $29.6M$28.8M$24.0M$15.2M$14.0M$10.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Operating cash flow $2.9M-$1.2M$3.1M$1.6M$5.8M—
Depreciation and amortisation $243.4K$237.8K$225.9K$362.6K$346.6K—
Capital expenditure $6.6M$144.9K$113.9K$40.2K$42.9K—
Investing cash flow -$10.8M-$9.5M-$7.7M-$120.9K-$1.1M—
Financing cash flow $7.4M$11.7M$6.9M$121.9K-$2.9M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-013870.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 10M 20M 30M Revenue, FY2021: 20.8M Gross profit, FY2021: 6.4M Net income, FY2021: 2.6M Revenue, FY2022: 19.2M Gross profit, FY2022: 6.2M Net income, FY2022: 2.7M Revenue, FY2023: 19.8M Gross profit, FY2023: 6.8M Net income, FY2023: 2.9M Revenue, FY2024: 23.5M Gross profit, FY2024: 9.5M Net income, FY2024: 3.7M Revenue, FY2025: 20.7M Gross profit, FY2025: 6M Net income, FY2025: 1.2M FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $20.8M $19.2M $19.8M $23.5M $20.7M
Gross profit — $6.4M $6.2M $6.8M $9.5M $6.0M
Net income — $2.6M $2.7M $2.9M $3.7M $1.2M

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $159.78B 57.5x 20.5%
EW Edwards Lifesciences Corp $51.34B 48.7x 11.5%
STE STERIS plc $22.63B 29.3x 8.7%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.80B 27.8x 7.2%
ALGN ALIGN TECHNOLOGY INC $10.98B 27.3x 0.9%
MSA MSA Safety Inc $7.03B 25.7x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $1.90B — 27.1%
CDRE Cadre Holdings, Inc. $1.28B 29.4x 7.5%